In response to the known and growing potential of the adenosinergic cascade to cancer immunotherapy, multiple players within the adenosinergic signaling axis have been investigated as potential anti-cancer targets, including CD39 (Bonnefoy et al., 2015), A2AR (Young et al., 2016) and CD73 (Ghalamfarsa et al., 2019). The gene discussed is ENTPD1; the disease is cancer.